Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study

BackgroundSystemic chemotherapy (SC) stands the only first-line treatment for advanced intrahepatic cholangiocarcinoma (iCCA) for the past few decades. Immune checkpoint inhibitors (ICIs) have been proved to provide additional benefit in disease control. However, oncological outcome of iCCA remains...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Zhenyun Yang, Weijie Wu, Zhiwen Hu, Yizhen Fu, Zili Hu, Yangxun Pan, Juncheng Wang, Jinbin Chen, Zhongguo Zhou, Yaojun Zhang, Minshan Chen, Dandan Hu
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2024-11-01
Reeks:	Frontiers in Immunology
Onderwerpen:	intrahepatic cholangiocarcinoma lenvatinib pembrolizumab systemic chemotherapy survival adverse events
Online toegang:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1494520/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!